ImmunoTargets and Therapy (Aug 2021)
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
Abstract
Michael Levy,1 Maureen A Mealy2 1Department of Neurology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA; 2Medical Affairs, Horizon Therapeutics, Deerfield, IL, USACorrespondence: Michael LevyMassachusetts General Hospital & Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USATel +1 617 726-7565Fax +1 888 523-4168Email [email protected]: Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system that preferentially targets the optic nerves and spinal cord, leading to visual loss and impaired mobility. Until 2019, no medications were FDA-approved for NMOSD treatment, and standard of care was based on mostly empiric and retrospective data. Therapies that target B cells emerged as a treatment strategy due to their fundamental role in disease pathogenesis. We explore different monoclonal antibodies directed at either CD20+ or CD19+ B cells that may have utilization in the treatment of NMOSD, discussing what is known regarding their efficacy and safety.Keywords: rituximab, inebilizumab, NMO, MOG, monoclonal
